In:
International Journal of Cancer, Wiley, Vol. 150, No. 7 ( 2022-04), p. 1166-1173
Kurzfassung:
What's new? Patients with cancer are at increased risk for venous thromboembolism (VTE). Here, the authors test the correlation between plasma tumor DNA (ptDNA) and VTE in patients with metastatic castration‐resistant prostate cancer. In prostate cancer, the concentration of ptDNA prior to treatment can predict clinical outcome. This study enrolled 180 patients who were receiving androgen deprivation therapy. The patients with high ptDNA had a greater incidence of VTE than those with low ptDNA. These results suggest that ptDNA could be a useful tool for assessing VTE risk and improving long‐term survival.
Materialart:
Online-Ressource
ISSN:
0020-7136
,
1097-0215
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2022
ZDB Id:
218257-9
ZDB Id:
1474822-8